1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ImmunoGen, Inc.
  6. Summary
    IMGN   US45253H1014

IMMUNOGEN, INC.

(IMGN)
  Report
Delayed Quote. Delayed Nasdaq - 05/27 04:00:00 pm
3.84 USD   +4.35%
05/27SECTOR UPDATE : Health Care Stocks End Higher
MT
05/27SECTOR UPDATE : Health Care
MT
05/27SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
3.57(c) 3.54(c) 3.47(c) 3.68(c) 3.84(c) Last
4 688 242 3 378 313 3 257 168 4 417 888 3 169 812 Volume
-0.28% -0.84% -1.98% +6.05% +4.35% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 85,7 M - -
Net income 2022 -206 M - -
Net cash position 2022 243 M - -
P/E ratio 2022 -4,55x
Yield 2022 -
Sales 2023 136 M - -
Net income 2023 -196 M - -
Net cash position 2023 180 M - -
P/E ratio 2023 -5,06x
Yield 2023 -
Capitalization 847 M 847 M -
EV / Sales 2022 7,05x
EV / Sales 2023 4,90x
Nbr of Employees 106
Free-Float 99,6%
More Financials
Company
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates... 
Sector
Biotechnology & Medical Research
Calendar
06/08 | 12:20pmPresentation
More about the company
Ratings of ImmunoGen, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about IMMUNOGEN, INC.
05/27SECTOR UPDATE : Health Care Stocks End Higher
MT
05/27SECTOR UPDATE : Health Care
MT
05/27SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/26ImmunoGen Says More Than 70% of Ovarian Cancer Patients Showed Tumor Reduction in Mirve..
MT
05/26ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Sora..
BU
05/26ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Sora..
CI
05/25ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
BU
05/24TRANSCRIPT : ImmunoGen, Inc. Presents at H.C. Wainwright Global Investment Conference 2022..
CI
05/23SECTOR UPDATE : Health Care Stocks Mixed Premarket Monday
MT
05/23IMMUNOGEN : Announces Acceptance of Biologics License Application for Mirvetuximab Soravta..
PU
05/23IMMUNOGEN, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibit..
AQ
05/23ImmunoGen Says FDA Approves Biologics License Application of Mirvetuximab Soravtansine ..
MT
05/23ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravt..
BU
05/23Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravt..
CI
05/23ImmunoGen Gets FDA Priority Review of Mirvetuximab Soravtansine in Ovarian Cancer
DJ
More news
News in other languages on IMMUNOGEN, INC.
05/27MISE À JOUR SECTORIELLE : Les actions du secteur de la santé terminent en hausse
05/27MISE À JOUR SECTORIELLE : Les actions du secteur de la santé progressent vendredi avant le..
05/26ImmunoGen affirme que plus de 70 % des patientes atteintes d'un cancer ovarien ont prés..
05/26ImmunoGen présente des analyses supplémentaires d'efficacité et de sécurité évaluant le..
05/23MISE À JOUR SECTORIELLE : Les actions du secteur de la santé sont mitigées lundi avant le ..
More news
Analyst Recommendations on IMMUNOGEN, INC.
More recommendations
Chart IMMUNOGEN, INC.
Duration : Period :
ImmunoGen, Inc. Technical Analysis Chart | IMGN | US45253H1014 | MarketScreener
Technical analysis trends IMMUNOGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 3,84 $
Average target price 11,50 $
Spread / Average Target 199%
EPS Revisions
Managers and Directors
Mark Joseph Enyedy President, Chief Executive Officer & Director
Susan Altschuller Chief Financial Officer & Senior Vice President
Stephen C. McCluski Chairman
Anna Berkenblit Chief Medical Officer & Senior Vice President
Thomas Ryll Vice President-Process & Analytical Development
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOGEN, INC.-48.25%847
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478